{"entity":{"id":"nct04665856","kind":"trial","name":"Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer","aka":["SKYSCRAPER-02C"],"tldr":"A phase 3 trial of Tiragolumab, Atezolizumab, Carboplatin and Etoposide in small-cell lung cancer, run by Hoffmann-La Roche, now completed.","summary":"Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer is a phase 3 interventional study registered as NCT04665856 by Hoffmann-La Roche, with 123 participants enrolled, started 2020-12-21 and reached its primary completion in 2023-08-31. Interventions recorded: Tiragolumab, Atezolizumab, Carboplatin, Etoposide and Tiragolumab Matching Placebo. Results have been posted on the registry.","status":"completed","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT04665856","url":"https://clinicaltrials.gov/study/NCT04665856"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["sclc","extensive-stage-sclc"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","platinum","tigit-blockade","topoisomerase-inhibitors"],"targets":[],"drugs":["tiragolumab","atezolizumab","carboplatin","etoposide"],"companies":["flatiron-health"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct04665856-j-thorac-oncol-2026"],"journals":[],"dependsOn":[],"notes":["Registry status on 22 September 2026: Completed (registry record last updated 18 September 2026; primary completion reached 31 August 2023)."],"nct":"NCT04665856","phase":"3","setting":"A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer","sponsor":"Hoffmann-La Roche","started":"2020-12-21","startedType":"actual","yearReported":2025,"enrolled":123,"enrolledBasis":"registry","outcomes":[{"endpoint":"Investigator-assessed Progression-free Survival (PFS) in the Primary Analysis Set (PAS)","primary":true,"unit":"months","arms":[{"name":"Placebo + Atezolizumab + Carboplatin + Etoposide","n":56,"value":5.39,"note":"95% CI 4.30 to 6.77; Figures from the ClinicalTrials.gov results section (first posted 2025-10-29), not from a publication"},{"name":"Tiragolumab + Atezolizumab + Carboplatin + Etoposide","n":54,"value":5.59,"note":"95% CI 4.53 to 7.89"}],"hr":0.65,"ci":[0.43,0.97],"p":"0.0348","source":"https://clinicaltrials.gov/study/NCT04665856?tab=results"},{"endpoint":"Overall Survival (OS) in the PAS","primary":true,"unit":"months","arms":[{"name":"Placebo + Atezolizumab + Carboplatin + Etoposide","n":56,"value":13.54,"note":"95% CI 10.35 to 22.44; Figures from the ClinicalTrials.gov results section (first posted 2025-10-29), not from a publication"},{"name":"Tiragolumab + Atezolizumab + Carboplatin + Etoposide","n":54,"value":18.69,"note":"95% CI 14.26 to 20.86"}],"hr":0.89,"ci":[0.56,1.4],"p":"0.6105","source":"https://clinicaltrials.gov/study/NCT04665856?tab=results"},{"endpoint":"Investigator-assessed Confirmed Objective Response Rate (ORR) in the PAS","unit":"%","arms":[{"name":"Placebo + Atezolizumab + Carboplatin + Etoposide","n":56,"value":58.9,"note":"95% CI 45.01 to 71.63; Figures from the ClinicalTrials.gov results section (first posted 2025-10-29), not from a publication"},{"name":"Tiragolumab + Atezolizumab + Carboplatin + Etoposide","n":54,"value":81.5,"note":"95% CI 68.13 to 90.30"}],"p":"0.0136","source":"https://clinicaltrials.gov/study/NCT04665856?tab=results"}]},"route":"/trials/nct04665856/","neighbours":{"cancer":[{"id":"extensive-stage-sclc","kind":"cancer","name":"Extensive-stage small-cell lung cancer","route":"/cancers/extensive-stage-sclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"},{"id":"tigit-blockade","kind":"technology","name":"TIGIT blockade","route":"/technologies/tigit-blockade/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"},{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"etoposide","kind":"drug","name":"Etoposide","route":"/drugs/etoposide/"},{"id":"tiragolumab","kind":"drug","name":"Tiragolumab","route":"/drugs/tiragolumab/"}],"company":[{"id":"flatiron-health","kind":"company","name":"Flatiron Health (Roche)","route":"/companies/flatiron-health/"}],"paper":[{"id":"paper-nct04665856-j-thorac-oncol-2026","kind":"paper","name":"SKYSCRAPER-02C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage SCLC in China","route":"/key-papers/paper-nct04665856-j-thorac-oncol-2026/"}]}}